EUCTR2022-001067-27-PT进行中（未招募）1 期
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA - Oral faCtor Eleven A iNhibitor asundexIan as novel anti-thrombotiC – STROKE study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 9,300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants must be = 18 years of age
- •2. Acute non-cardioembolic stroke or high-risk TIA
- •3. Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6200
排除标准
- •1. Ischemic stroke = 7 days before the index stroke event
- •2. Index stroke following procedures or strokes due to other rare causes
- •3. History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation
研究者
相似试验
招募中
3 期
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIAstrokeNL-OMON51380Bayer105
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsEUCTR2022-001067-27-NLBayer AG9,300
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsPrevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attackMedDRA version: 20.0Level: PTClassification code 10049165Term: Cerebrovascular accident prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 22.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10072760Term: Transient ischemic attackSystem Organ Class: 100000004852EUCTR2022-001067-27-DKBayer AG9,300
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsEUCTR2022-001067-27-LTBayer AG9,300
进行中（未招募）
1 期
A study to learn more about asundexian (also called BAY2433334) for prevention of ischemic stroke in male and female participants aged 18 years and older who already had such a stroke due to a blood clot that formed outside the heart and travelled to the brain, or temporary stroke-like symptomsPrevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attackMedDRA version: 20.0Level: PTClassification code 10049165Term: Cerebrovascular accident prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 22.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10072760Term: Transient ischemic attackSystem Organ Class: 100000004852EUCTR2022-001067-27-FIBayer AG9,300